logo-loader

Zelda Therapeutics Ltd starts countdown to ASX listing

Published: 08:00 27 Oct 2016 AEDT

vis_handel_eon_energytrading1_300dpi
Zelda is focused on medical cannabis.

Zelda Therapeutics Ltd's (ASX:ZLD) transition to being a publically listed medical cannabis focused company is almost complete.

Investor interest has been strong in the new company, with valid subscriptions of over $4 million already received.

Zelda (previously Gleneagle Gold, GLN) expects its shares to be reinstated to the ASX on the 25th November 2016.

Today the ASX granted a waiver from listing rule 14.7 to the extent necessary to permit the company to issue securities, as approved by shareholders at the general meeting held on 25 July 2016.

This is purely a technical issue related to the extended timetable and does not affect any material aspect of the transaction.

Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.

The company has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 6 minutes ago